Nursen Cetrez | Karolinska Institutet

Stäng

Ett medicinskt universitet

Sök

Meny

Ett medicinskt universitet

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Läkare
Projektsamordnare, Cell och genterapi (Grupp Evren Alici)

Vetenskaplig koordinator, NextGenNK kompetenscentrum
Marmara Universitet, Medicinska Fakulteten, Istanbul, Turkiet (2014-2021)

Artiklar

Article: RHEUMATOLOGY. 2024;:keae216

Patients with neuropsychiatric involvement systemic lupus erythematosus experience poorer health-related quality of life and more fatigue than systemic lupus erythematosus patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity.

Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: RHEUMATOLOGY. 2024;63(3):798-808

Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.

Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Article: KIDNEY INTERNATIONAL REPORTS. 2023;8(9):1822-1830

Effect of Belimumab on Preventing de novo Renal Lupus Flares.

Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau FA; Sjöwall C; Rovin BH
Journal article: BEHAVIOURAL BRAIN RESEARCH. 2021;397:112923

High intensity interval training protects from Post Traumatic Stress Disorder induced cognitive impairment.

Koyuncuoğlu T; Sevim H; Çetrez N; Meral Z; Gönenç B; Kuntsal Dertsiz E; Akakın D; Yüksel M; Kasımay Çakır Ö

Alla övriga publikationer

Conference publication: 2024;:a59.1-a5a59

P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus

Lourenço MH; Cetrez N; Tsoi A; Lindblom J; Nikolopoulos D; Parodis I
Conference publication: 2024;:a58.2-a5a58

P22 Consistent benefits from belimumab irrespective of antiphospholipid autoantibody profile, yet not in the presence of lupus anticoagulant

Tsoi A; Lindblom J; Cetrez N; Parodis I
Conference publication: 2024;:a39-a40

O42 Patients with systemic lupus erythematosus experience poor health-related quality of life despite a low disease activity state or remission

Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Nikpour M; Levitsky A; Strand V
Conference publication: 2024;:a28.2-a2a29

O28 Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual

Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a14-a15

O11 Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus

Gatto M; Depascale R; Cetrez N; Lindblom J; Nikolopoulos D; Doria A; Parodis I
Conference publication: 2024;:a119.1-a1a119

P110 Impact of neuropsychiatric involvement on health-related quality of life in patients with systemic lupus erythematosus

Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a86.1-a8a86

P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: knowledge-driven models outperformed data-driven models

Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a85.2-a8a86

P61 Harnessing machine learning to predict neuropsychiatric events in systemic lupus erythematosus

Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a36.2-a3a37

O39 Immune deposit resorption in per-protocol repeat kidney biopsy performed in patients with proliferative lupus nephritis

Cetrez N; Tamirou F; Nieuwland S; Aydin S; Parodis I; Houssiau FA
Conference publication: 2023;:a51.1-a5a51

LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

Parodis I; Lindblom J; Çetrez N; Palazzo L; Ala H; Houssiau F; Sjöwall C; Rovin B
Conference publication: 2023;:a149.1-a1a149

LP-170 Predictors of neuropsychiatric flares In Patients With Systemic Lupus Erythematosus: Results From Five Phase III clinical trials of belimumab

Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1088.1-101088

PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB

Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:909.2-90910

PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS - TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB

Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin BH
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:45

Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase Ill clinical trials of belimumab

Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:46

De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab. Implications for revisiting belimumab dose

Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin B

Anställningar

Projektsamordnare, Medicin, Huddinge, Karolinska Institutet, 2024-2025
Forskningsassistent, Medicin, Solna, Karolinska Institutet, 2022-2024

Nyheter från KI

Kalenderhändelser från KI